Shares of Anglo-Swedish pharma giant AstraZeneca (AZN) are down over 11 percent year-to-date as the company gears up to face another patent cliff this year. This pales before the 4 percent gain by its predator Pfizer and Merck’s 8 percent advance.
Forex – financial instrument.Forex news
Shares of Anglo-Swedish pharma giant AstraZeneca (AZN) are down over 11 percent year-to-date as the company gears up to face another patent cliff this year. This pales before the 4 percent gain by its predator Pfizer and Merck’s 8 percent advance.